CD4-T Lymphocyte in Cervical Cancer Patients on Pre-and Post-Chemotherapy
DOI:
https://doi.org/10.24293/ijcpml.v26i1.1367Keywords:
CD4, neoadjuvant, advanced stage, chemotherapy, cervical cancerAbstract
Cervical cancer is a gynecology cancer with the highest incidence in the Dr.Soetomo Hospital, Surabaya. Neoadjuvant chemotherapy with cisplatin has been used to increase radiosensitivy of cancer cells before radiotherapy done in advanced stage cervical cancer patients. This research aimed to know the differences of CD4-T lymphocyte profile in stage IIIB patient before and after chemotheraphy administration. This research was done in February-September 2018. Seventeen patients out of 31 stage IIIB cervical cancer patients planned to receive neoadjuvan chemotherapy with cisplatin every 3 weeks for 3 series were checked for the CD4+ T lymphocyte count and percentage. The examinations were done before the first and after the third chemotherapy administration. Mean±SD of the CD4-T lymphocyte count before chemotherapy was 817±314 cells/μL and mean±SD of the CD4-T lymphocyte percentage was 38.96±8.47%. While mean±SD of the CD4-T lymphocyte count after chemotherapy was 881±335 cells/μL and mean±SD of the CD4-T lymphocyte percentage was 39.01±8.50%. There was no significant difference of CD4-T lymphocyte count between before and after chemotherapy (p=0.471). There was also no significant difference of CD4-T lymphocyte percentage between before and after chemotherapy (p=0.866). Both the CD4-T lymphocyte count and percentage tended to increase in postchemotherapy condition. The CD4-T lymphocyte count and percentage were not significantly different between before and after chemotherapy administration in stage IIIB cervical cancer patients. Both the CD4-T lymphocyte count and percentage tended to increase in postchemotherapy condition.
Downloads
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int.J. Cancer. 2014; 136:E359-E386.
Rasjidi I. Epidemiologi Kanker Serviks. Indonesian Journal of Cancer. 2009 Juli-September; 3: 103-108.
Mathers C, Boerma T, Fat DM. The Global Burden of Disease : Update 2004 Geneva: WHO Press, 2004.part 2-3; p.12-37
Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S. Cancer in Thailand Volume V. Bangkok: National Cancer Institute, 2010. Chapter 2; p.52-55
Belhadj H, Berek J, Bermudez A, Bhatla N, Cain J, et al. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. International Journal of Gynecology and Obstetrics. 2014; 125:97-98.
Kokka F, Bryant A, Brockbank E, Powell M, Oram D. Hysterectomy with radiotherapy or chemotherapy or both for. Cochrane Database of Systematic Reviews. 2015;(4).
Kesic V. Management of cervical cancer. European Journal of Surgical Oncology. 2006; 32:832-837.
Gerloni M, Zanett M. CD4 T cells in tumor immunity. Springer Semin Immun. 2005;27:37–48.
Anazoeze M, Sunday O, Obike I, Awelw C, Kenechi M . Comparison of absolute neutrophil to CD4 lymphocyte values as a marker of immunosuppression in cancer patients on cytotoxic chemotherapy. African Health Science. 2015; 15(2): 581-589
Abbas A, Lichtman A, Pillai S. Cellular and Molecular Immunology. 8th edition. Philadelphia: Elsevier Saunder, 2015. Chapter 18; p.383-396
Adam JK, Odhav B, Bhoola KD. Immune respond in cancer. Pharmacology & Therapeutics. 2003; 99:113-132.
Gemignani M, Maiman M, Fruchter R et al . CD4 Lymphocytes in Women with Invasive and Preinvasive Cervical Neoplasia. Gynecologic Oncology. 1995; 59:364-369.
Madu AJ, Ocheni S, Ibegbulam OG, Aguwa EN, Madu KA. Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy. Annals of Medical and Health Sciences Research. 2013; 3(4):408-503.
Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer : an update. Expert Rev. Anticancer Ther. 2015; 15(10):1171-1181.
Marth C, Landoni F, Mahner S, et al. Cervical cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Annals of Oncology. 2017; 28(4):iv72-iv83.
De Biasi A, Villena-Vargas J, Adusumilli PS. Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence. Clin Cancer Res. 2014; 20(21): 5384-5391.
Agustiansyah P, Sanif R, Thodorus, Nurmila N. Cluster of Differentiation as Predictor of Therapy Response to Neoadjuvant Chemotherapy in Advanced Stage Cervical Cancer. J Res Med Dent Sci. 2018; 6 (1):209-212.
Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr.1989; 2(2): 114-24
Ostroumov D, Fekete-Drismusz N, Sabarowski M, Kuhnel F, Woller N. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018; 75(4):689-713
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
